Literature DB >> 27001888

Renal denervation for resistant hypertension: no.

Stefano Taddei1, Elisa Dal Canto2, Rosa Maria Bruno2.   

Abstract

In recent years, catheter-based radiofrequency denervation of the renal arteries (RDN) has emerged as a potential treatment for resistant hypertension. Though initial non-randomized and randomized small studies demonstrate large reductions in office blood pressure, RDN superiority to conventional treatment is not confirmed either by randomized controlled trials or by large international registries. Increasing evidence supports the hypothesis that a rational pharmacological therapeutic scheme is equally or more effective; this approach, together with an intervention aimed at increasing patient's compliance with treatment, might solve most of the cases of refractory hypertension. Thus, based on current evidence, renal denervation should not be routinely used to treat resistant hypertension. Though the possibility that RDN might be useful in other subsets of hypertensive patients exists, it has never been proven. Thus, its use should be limited to extreme situations, when all other possible treatments have failed.

Entities:  

Keywords:  Blood pressure; Compliance; Renal denervation; Resistant hypertension

Mesh:

Substances:

Year:  2016        PMID: 27001888     DOI: 10.1007/s11739-016-1428-4

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  22 in total

1.  Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study.

Authors:  Stella Douma; Konstantinos Petidis; Michael Doumas; Panagiota Papaefthimiou; Areti Triantafyllou; Niki Kartali; Nikolaos Papadopoulos; Konstantinos Vogiatzis; Chrysanthos Zamboulis
Journal:  Lancet       Date:  2008-06-07       Impact factor: 79.321

Review 2.  Potential new indications and future studies.

Authors:  Isabella Sudano; Georg Noll; Thomas F Luscher
Journal:  EuroIntervention       Date:  2013-05       Impact factor: 6.534

3.  A randomized and controlled study of noninvasive hemodynamic monitoring as a guide to drug treatment of uncontrolled hypertensive patients.

Authors:  Fadl Elmula M Fadl Elmula; Paola Rebora; Anneli Talvik; Sabrina Salerno; Eliza Miszkowska-Nagórna; Xiaoqiu Liu; Marika Heinpalu-Kuum; Tommaso Comotti; Anne C Larstorp; Morten Rostrup; Ewa Świerblewska; Maria Grazia Valsecchi; Sverre E Kjeldsen; Margus Viigimaa; Krzysztof Narkiewicz; Gianfranco Parati; Stéphane Laurent
Journal:  J Hypertens       Date:  2015-12       Impact factor: 4.844

Review 4.  Effect of CPAP on blood pressure in patients with obstructive sleep apnea and resistant hypertension: a systematic review and meta-analysis.

Authors:  Christos Varounis; Vasiliki Katsi; Ioannis E Kallikazaros; Dimitrios Tousoulis; Christodoulos Stefanadis; John Parissis; John Lekakis; Charalampos Siristatidis; Athanasios J Manolis; Thomas Makris
Journal:  Int J Cardiol       Date:  2014-04-30       Impact factor: 4.164

5.  Resistant hypertension revisited: a comparison of two university-based cohorts.

Authors:  Jay P Garg; William J Elliott; Amy Folker; Munavvar Izhar; Henry R Black
Journal:  Am J Hypertens       Date:  2005-05       Impact factor: 2.689

6.  Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension.

Authors:  Rodrigo P Pedrosa; Luciano F Drager; Carolina C Gonzaga; Marcio G Sousa; Lílian K G de Paula; Aline C S Amaro; Celso Amodeo; Luiz A Bortolotto; Eduardo M Krieger; T Douglas Bradley; Geraldo Lorenzi-Filho
Journal:  Hypertension       Date:  2011-10-03       Impact factor: 10.190

7.  Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial.

Authors:  Jan Václavík; Richard Sedlák; Martin Plachy; Karel Navrátil; Jirí Plásek; Jirí Jarkovsky; Tomás Václavík; Roman Husár; Eva Kociánová; Milos Táborsky
Journal:  Hypertension       Date:  2011-05-02       Impact factor: 10.190

8.  Predictors of resistant hypertension in an unselected sample of an adult male population in Italy.

Authors:  Antonio Barbato; Ferruccio Galletti; Roberto Iacone; Francesco P Cappuccio; Giovanni Rossi; Renato Ippolito; Antonella Venezia; Eduardo Farinaro; Pasquale Strazzullo
Journal:  Intern Emerg Med       Date:  2011-03-10       Impact factor: 3.397

9.  Magnitude of blood pressure reduction in the placebo arms of modern hypertension trials: implications for trials of renal denervation.

Authors:  Hitesh C Patel; Carl Hayward; Baris Ata Ozdemir; Stuart D Rosen; Henry Krum; Alexander R Lyon; Darrel P Francis; Carlo di Mario
Journal:  Hypertension       Date:  2014-11-17       Impact factor: 10.190

10.  Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.

Authors:  Bryan Williams; Thomas M MacDonald; Steve Morant; David J Webb; Peter Sever; Gordon McInnes; Ian Ford; J Kennedy Cruickshank; Mark J Caulfield; Jackie Salsbury; Isla Mackenzie; Sandosh Padmanabhan; Morris J Brown
Journal:  Lancet       Date:  2015-09-20       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.